Skip to content

Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) and Substance Use: A Pilot Study

Treatment Engagement in Families With Substance Use and Psychosis: A Pilot Study

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05380583
Enrollment
65
Registered
2022-05-19
Start date
2022-05-19
Completion date
2026-01-23
Last updated
2026-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol, Bipolar Disorder, Cannabis, Family, Marijuana, Mental Disorder, Psychosis, Schizoaffective Disorder, Schizophrenia, Substance Use, Substance Use Disorders

Brief summary

The purpose of this study is to evaluate Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) for families experiencing early psychosis and substance use delivered exclusively or primarily via telehealth (video conferencing).

Detailed description

The intervention aims to improve treatment engagement, substance use patterns, and family wellbeing. To assess preliminary outcomes of the intervention, this study compares CRAFT-EP plus treatment as usual (TAU) compared to TAU alone. Family members will be randomized to CRAFT-EP + TAU or TAU alone. Data on family members and clients with psychosis will be collected for assessment purposes; if a client with psychosis does not have a family member participating in the study, the client with psychosis will be automatically be assigned to the TAU alone group. Total target enrollment is 40 family members and 40 clients with psychosis. Given that family members may participate without a corresponding client with psychosis due to fear of disclosing their participation in the study to the client or client lack of interest, and because the intervention works directly with family members and indirectly with clients, data collected from clients with or without a corresponding family member participating in the study will be hypothesis generating.

Interventions

BEHAVIORALCRAFT-EP

CRAFT-EP is a behavioral intervention delivered via telehealth with the option for one in-person session (when local guidelines allow in-person care without masks). The coaching session topics include self-care, communication, functional analysis, positive reinforcement, treatment engagement, natural consequences, problem solving, and planning next steps. The intervention is designed for families of individuals experiencing psychosis and substance use who are enrolled or seeking enrollment in early psychosis outpatient services. Participants will be asked to complete assessments at pre-, mid- (approximately week 4), post-intervention, and a follow-up assessment approximately 12 weeks post-intervention.

BEHAVIORALTAU

Participants may continue to receive their ongoing treatment, if any, which may include psychosocial and/or pharmacological interventions.

Sponsors

Mclean Hospital
Lead SponsorOTHER
National Institute on Drug Abuse (NIDA)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

for Family Members: * Ages 18-70. * Having a relative who: 1. Is a client with early course psychosis (schizophrenia, schizoaffective disorder, schizophreniform, psychosis not otherwise specified (NOS), delusional disorder, brief psychotic disorder, major depression with psychosis, and bipolar disorder with psychosis (as reported by family member, clinician, or chart review)) with first onset in the past 6 years, and 2. Used alcohol or cannabis in the past 30 days and/or has no apparent immediate interest in abstinence (responding "No" to "Do you think they want to quit right now?" in reference to overall substance use). 3. Family member has concerns about the relative's substance use. * The person(s) who can best describe the client with psychosis. * At least 4 days per month contact with the client. * Access to a computer with internet or mobile phone with video conferencing capabilities. * Ability to provide written informed consent. * Speak and read English.

Exclusion criteria

for Family Members: * DSM-5 moderate or severe substance use disorder in the past year. * Lifetime psychotic disorder. * History of domestic violence with the client relative that would interfere with the ability to safely follow through with the intervention plan. * Psychiatric, cognitive, or medical impairments that would interfere with the ability to follow through with the intervention plan. * Prior participation of a family member of the client in the study program. * Significant prior experience with CRAFT (e.g., having completed a CRAFT course prior to study enrollment) Inclusion Criteria for Client Relatives: * Ages 18-35. * First episode psychosis onset in the past 6 years with a Diagnostic and Statistical Manual (DSM)-5 diagnosis of affective (bipolar disorder or major depressive disorder with psychotic features) or non- affective psychosis (schizophrenia spectrum disorder) * Used alcohol or cannabis in the past 30 days and/or has no apparent immediate interest in abstinence (responding "No" to "Do you want to quit right now?" in reference to overall substance use). * They or others have concerns about the client's substance use. * Ability to provide written informed consent (or assent with their legal guardian providing informed consent) * Speak and read English.

Design outcomes

Primary

MeasureTime frameDescription
Family Wellbeing: DepressionBaseline, mid-intervention (week 4), post-intervention (week 8)Beck Depression Inventory-II total; scores range from 0 to 63 with higher scores representing more severe depressive symptoms.

Secondary

MeasureTime frameDescription
Family Wellbeing: AnxietyBaseline, mid-intervention (week 4), post-intervention (week 8)State-Trait Anxiety Inventory-Short Form; total scores range from 6 to 24 with higher scores representing more severe anxiety symptoms. Raw total scores transformed to the original 20-item scale range from 20 to 80 with higher scores representing more severe anxiety symptoms.
Family Wellbeing: RelationshipBaseline, mid-intervention (week 4), post-intervention (week 8)General Happiness item on Relationship Happiness Scale; scores range from 1 to 10 with higher scores representing greater relationship happiness.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORJulie M McCarthy, PhD

Mclean Hospital

Participant flow

Recruitment details

Participants were recruited from May 2022 through August 2025 from the United States.

Pre-assignment details

Family member participant data are reported in the Results Outcome Measures Section. Clients with psychosis were enrolled and completed assessments for hypothesis generating purposes. They did not complete the intervention, and they have no pre-specified primary or secondary outcome data; thus, no data from client with psychosis are reported in the Results Outcome Measures Section.

Baseline characteristics

Characteristic
Age, Continuous53.95 years
STANDARD_DEVIATION 6.29
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
21 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
1 Participants
Race (NIH/OMB)
Black or African American
2 Participants
Race (NIH/OMB)
More than one race
1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
3 Participants
Race (NIH/OMB)
White
16 Participants
Region of Enrollment
United States
18 participants
Sex: Female, Male
Female
20 Participants
Sex: Female, Male
Male
1 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 210 / 220 / 40 / 18
other
Total, other adverse events
1 / 213 / 222 / 46 / 18
serious
Total, serious adverse events
0 / 210 / 220 / 40 / 18

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026